Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Philips launches foetal-maternal monitors in EU, Africa and Middle East:

This article was originally published in Clinica

Executive Summary

Philips Medical Systems has launched two new foetal-maternal ultrasound monitors across a number of European, African and Middle Eastern countries. Both the Avalon FM40 antepartum (pre-birth) and FM50 intrapartum (during labour) monitors feature a built-in colour monitor, and an external display with touch-screen capability that can be mounted in a different room to the patient. This allows the doctor to interact with the monitor even when they are away from the patient's bedside. Both monitors can measure maternal blood pressure, SpO2, maternal and foetal ECG and maternal heart rate. The systems can monitor the mother and up to three babies simultaneously. In addition, the transducers on both devices are constructed with a soft material to increase patient comfort, said the firm.

You may also be interested in...



Korean Bioclusters Offer Tax, Other Incentives To Attract Global Firms, Talent

South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.

CDC Panel Backs Pfizer’s Maternal RSV Vaccine But Leaves Room For AstraZeneca/Sanofi’s Beyfortus

Abrysvo is recommended for use in pregnant people 32-36 weeks gestation if administered from September to January. For infants whose mothers were not vaccinated in this window, nirsevimab is recommended for prevention of respiratory syncytial virus infection.

Jardiance Improves Double-Digit Growth Potential With US Approval In CKD

Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT046062

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel